Axsome Therapeutics (AXSM) is a company working to bring drugs into the clinic, and through FDA approval for the indications of pain, and CNS disorders. We are focusing on their unique mechanism of action CNS drug, AXS-05 at this time. AXS-05 combines dextromethorphan (DM), and bupropion (BP), and is targeting the indications below.
Share Out: 19M
Market Cap: 135M
Cash: 44M
Patent: 2034
Like other drug development companies, Axsome has identified Dextromethorphan as a potential treatment for CNS disorders, and is using bupropion as an inhibitor, with potential increased efficacy affect. I expect the company to raise cash soon through a secondary offering, to fund future clinical trials. Thank you for reading.
- Treatment Resistant Depression Disorder: phase 3 initiated NCT02741791.
- Agitation in Alzheimer's disease phase 2/3 planned end of 2016.
Share Out: 19M
Market Cap: 135M
Cash: 44M
Patent: 2034
Like other drug development companies, Axsome has identified Dextromethorphan as a potential treatment for CNS disorders, and is using bupropion as an inhibitor, with potential increased efficacy affect. I expect the company to raise cash soon through a secondary offering, to fund future clinical trials. Thank you for reading.
No comments:
Post a Comment